A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

NCT ID: NCT01959529

Last Updated: 2019-07-24

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

7637 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-29

Study Completion Date

2016-10-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial is conducted globally. The aim of this trial is to compare cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Insulin degludec (IDeg)

All subjects will continue their current antidiabetic therapy except for the basal insulin component (if any) that will be replaced by the investigational product.

Group Type EXPERIMENTAL

insulin degludec

Intervention Type DRUG

Injected once daily subcutaneously (s.c., under the skin)

Insulin glargine (IGlar)

All subjects will continue their current antidiabetic therapy except for the basal insulin component (if any) that will be replaced by the investigational product.

Group Type ACTIVE_COMPARATOR

insulin glargine

Intervention Type DRUG

Injected once daily subcutaneously (s.c., under the skin)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

insulin degludec

Injected once daily subcutaneously (s.c., under the skin)

Intervention Type DRUG

insulin glargine

Injected once daily subcutaneously (s.c., under the skin)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Inclusion Criteria: - Type 2 diabetes - Age above or equal to 50 years with predefined previous cardiovascular disease(s) or renal disease or age above or equal to 60 years with predefined cardiovascular risk factors - HbA1c (glycosylated haemoglobin) above or equal to 7.0% or HbA1c below 7.

Exclusion Criteria

0% and current insulin treatment corresponding to above or equal to 20 U of basal insulin per day - One or more oral or injectable antidiabetic agent(s) Exclusion Criteria: - An acute coronary or cerebrovascular event in the previous 60 days - Planned coronary, carotid or peripheral artery revascularisation - Chronic heart failure NYHA (New York Heart Association) class IV - Current or past (within the last 5 years) malignant neoplasms (except basal cell and squamous cell skin carcinoma)
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novo Nordisk A/S

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Global Clinical Registry (GCR, 1452)

Role: STUDY_DIRECTOR

Novo Nordisk A/S

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Novo Nordisk Investigational Site

Birmingham, Alabama, United States

Site Status

Novo Nordisk Investigational Site

Birmingham, Alabama, United States

Site Status

Novo Nordisk Investigational Site

Montgomery, Alabama, United States

Site Status

Novo Nordisk Investigational Site

Montgomery, Alabama, United States

Site Status

Novo Nordisk Investigational Site

Gilbert, Arizona, United States

Site Status

Novo Nordisk Investigational Site

Glendale, Arizona, United States

Site Status

Novo Nordisk Investigational Site

Litchfield Park, Arizona, United States

Site Status

Novo Nordisk Investigational Site

Phoenix, Arizona, United States

Site Status

Novo Nordisk Investigational Site

Tucson, Arizona, United States

Site Status

Novo Nordisk Investigational Site

Tucson, Arizona, United States

Site Status

Novo Nordisk Investigational Site

Tucson, Arizona, United States

Site Status

Novo Nordisk Investigational Site

Little Rock, Arkansas, United States

Site Status

Novo Nordisk Investigational Site

Little Rock, Arkansas, United States

Site Status

Novo Nordisk Investigational Site

Searcy, Arkansas, United States

Site Status

Novo Nordisk Investigational Site

Chula Vista, California, United States

Site Status

Novo Nordisk Investigational Site

Concord, California, United States

Site Status

Novo Nordisk Investigational Site

Downey, California, United States

Site Status

Novo Nordisk Investigational Site

Duarte, California, United States

Site Status

Novo Nordisk Investigational Site

Encino, California, United States

Site Status

Novo Nordisk Investigational Site

Fresno, California, United States

Site Status

Novo Nordisk Investigational Site

Greenbrae, California, United States

Site Status

Novo Nordisk Investigational Site

Huntington Beach, California, United States

Site Status

Novo Nordisk Investigational Site

Inglewood, California, United States

Site Status

Novo Nordisk Investigational Site

La Jolla, California, United States

Site Status

Novo Nordisk Investigational Site

La Mesa, California, United States

Site Status

Novo Nordisk Investigational Site

Lancaster, California, United States

Site Status

Novo Nordisk Investigational Site

Long Beach, California, United States

Site Status

Novo Nordisk Investigational Site

Los Alamitos, California, United States

Site Status

Novo Nordisk Investigational Site

Mission Hills, California, United States

Site Status

Novo Nordisk Investigational Site

Montclair, California, United States

Site Status

Novo Nordisk Investigational Site

Monterey, California, United States

Site Status

Novo Nordisk Investigational Site

North Hollywood, California, United States

Site Status

Novo Nordisk Investigational Site

Palm Springs, California, United States

Site Status

Novo Nordisk Investigational Site

Poway, California, United States

Site Status

Novo Nordisk Investigational Site

San Diego, California, United States

Site Status

Novo Nordisk Investigational Site

San Diego, California, United States

Site Status

Novo Nordisk Investigational Site

San Ramon, California, United States

Site Status

Novo Nordisk Investigational Site

Santa Ana, California, United States

Site Status

Novo Nordisk Investigational Site

Sherman Oaks, California, United States

Site Status

Novo Nordisk Investigational Site

Thousand Oaks, California, United States

Site Status

Novo Nordisk Investigational Site

Tustin, California, United States

Site Status

Novo Nordisk Investigational Site

Ventura, California, United States

Site Status

Novo Nordisk Investigational Site

Vista, California, United States

Site Status

Novo Nordisk Investigational Site

Westminster, California, United States

Site Status

Novo Nordisk Investigational Site

Colorado Springs, Colorado, United States

Site Status

Novo Nordisk Investigational Site

Denver, Colorado, United States

Site Status

Novo Nordisk Investigational Site

Denver, Colorado, United States

Site Status

Novo Nordisk Investigational Site

Golden, Colorado, United States

Site Status

Novo Nordisk Investigational Site

Danbury, Connecticut, United States

Site Status

Novo Nordisk Investigational Site

Norwalk, Connecticut, United States

Site Status

Novo Nordisk Investigational Site

Waterbury, Connecticut, United States

Site Status

Novo Nordisk Investigational Site

Boca Raton, Florida, United States

Site Status

Novo Nordisk Investigational Site

Boynton Beach, Florida, United States

Site Status

Novo Nordisk Investigational Site

Bradenton, Florida, United States

Site Status

Novo Nordisk Investigational Site

Brandon, Florida, United States

Site Status

Novo Nordisk Investigational Site

Clearwater, Florida, United States

Site Status

Novo Nordisk Investigational Site

Cooper City, Florida, United States

Site Status

Novo Nordisk Investigational Site

Fleming Island, Florida, United States

Site Status

Novo Nordisk Investigational Site

Fort Lauderdale, Florida, United States

Site Status

Novo Nordisk Investigational Site

Gainesville, Florida, United States

Site Status

Novo Nordisk Investigational Site

Green Cove Springs, Florida, United States

Site Status

Novo Nordisk Investigational Site

Hialeah, Florida, United States

Site Status

Novo Nordisk Investigational Site

Jacksonville, Florida, United States

Site Status

Novo Nordisk Investigational Site

Jacksonville, Florida, United States

Site Status

Novo Nordisk Investigational Site

Miami, Florida, United States

Site Status

Novo Nordisk Investigational Site

Miami, Florida, United States

Site Status

Novo Nordisk Investigational Site

Miami, Florida, United States

Site Status

Novo Nordisk Investigational Site

Miami, Florida, United States

Site Status

Novo Nordisk Investigational Site

Miami, Florida, United States

Site Status

Novo Nordisk Investigational Site

Naples, Florida, United States

Site Status

Novo Nordisk Investigational Site

New Port Richey, Florida, United States

Site Status

Novo Nordisk Investigational Site

Orlando, Florida, United States

Site Status

Novo Nordisk Investigational Site

Panama City, Florida, United States

Site Status

Novo Nordisk Investigational Site

Ponte Vedra, Florida, United States

Site Status

Novo Nordisk Investigational Site

Port Charlotte, Florida, United States

Site Status

Novo Nordisk Investigational Site

Port Orange, Florida, United States

Site Status

Novo Nordisk Investigational Site

South Miami, Florida, United States

Site Status

Novo Nordisk Investigational Site

Tampa, Florida, United States

Site Status

Novo Nordisk Investigational Site

Tampa, Florida, United States

Site Status

Novo Nordisk Investigational Site

Atlanta, Georgia, United States

Site Status

Novo Nordisk Investigational Site

Decatur, Georgia, United States

Site Status

Novo Nordisk Investigational Site

Dunwoody, Georgia, United States

Site Status

Novo Nordisk Investigational Site

Lawrenceville, Georgia, United States

Site Status

Novo Nordisk Investigational Site

Roswell, Georgia, United States

Site Status

Novo Nordisk Investigational Site

Savannah, Georgia, United States

Site Status

Novo Nordisk Investigational Site

Honolulu, Hawaii, United States

Site Status

Novo Nordisk Investigational Site

Idaho Falls, Idaho, United States

Site Status

Novo Nordisk Investigational Site

Addison, Illinois, United States

Site Status

Novo Nordisk Investigational Site

Champaign, Illinois, United States

Site Status

Novo Nordisk Investigational Site

Chicago, Illinois, United States

Site Status

Novo Nordisk Investigational Site

Chicago, Illinois, United States

Site Status

Novo Nordisk Investigational Site

Crystal Lake, Illinois, United States

Site Status

Novo Nordisk Investigational Site

Gurnee, Illinois, United States

Site Status

Novo Nordisk Investigational Site

Hines, Illinois, United States

Site Status

Novo Nordisk Investigational Site

Springfield, Illinois, United States

Site Status

Novo Nordisk Investigational Site

Springfield, Illinois, United States

Site Status

Novo Nordisk Investigational Site

Brownsburg, Indiana, United States

Site Status

Novo Nordisk Investigational Site

Evansville, Indiana, United States

Site Status

Novo Nordisk Investigational Site

Franklin, Indiana, United States

Site Status

Novo Nordisk Investigational Site

Greenfield, Indiana, United States

Site Status

Novo Nordisk Investigational Site

Indianapolis, Indiana, United States

Site Status

Novo Nordisk Investigational Site

Michigan City, Indiana, United States

Site Status

Novo Nordisk Investigational Site

Muncie, Indiana, United States

Site Status

Novo Nordisk Investigational Site

Council Bluffs, Iowa, United States

Site Status

Novo Nordisk Investigational Site

Wichita, Kansas, United States

Site Status

Novo Nordisk Investigational Site

Lexington, Kentucky, United States

Site Status

Novo Nordisk Investigational Site

Lexington, Kentucky, United States

Site Status

Novo Nordisk Investigational Site

Louisville, Kentucky, United States

Site Status

Novo Nordisk Investigational Site

Louisville, Kentucky, United States

Site Status

Novo Nordisk Investigational Site

Madisonville, Kentucky, United States

Site Status

Novo Nordisk Investigational Site

Monroe, Louisiana, United States

Site Status

Novo Nordisk Investigational Site

New Orleans, Louisiana, United States

Site Status

Novo Nordisk Investigational Site

Shreveport, Louisiana, United States

Site Status

Novo Nordisk Investigational Site

Slidell, Louisiana, United States

Site Status

Novo Nordisk Investigational Site

Bangor, Maine, United States

Site Status

Novo Nordisk Investigational Site

Hyattsville, Maryland, United States

Site Status

Novo Nordisk Investigational Site

Rockville, Maryland, United States

Site Status

Novo Nordisk Investigational Site

Watertown, Massachusetts, United States

Site Status

Novo Nordisk Investigational Site

Worcester, Massachusetts, United States

Site Status

Novo Nordisk Investigational Site

Ann Arbor, Michigan, United States

Site Status

Novo Nordisk Investigational Site

Ann Arbor, Michigan, United States

Site Status

Novo Nordisk Investigational Site

Buckley, Michigan, United States

Site Status

Novo Nordisk Investigational Site

Detroit, Michigan, United States

Site Status

Novo Nordisk Investigational Site

Detroit, Michigan, United States

Site Status

Novo Nordisk Investigational Site

Kalamazoo, Michigan, United States

Site Status

Novo Nordisk Investigational Site

Livonia, Michigan, United States

Site Status

Novo Nordisk Investigational Site

Troy, Michigan, United States

Site Status

Novo Nordisk Investigational Site

Olive Branch, Mississippi, United States

Site Status

Novo Nordisk Investigational Site

Hazelwood, Missouri, United States

Site Status

Novo Nordisk Investigational Site

Jefferson City, Missouri, United States

Site Status

Novo Nordisk Investigational Site

Kansas City, Missouri, United States

Site Status

Novo Nordisk Investigational Site

Billings, Montana, United States

Site Status

Novo Nordisk Investigational Site

Kalispell, Montana, United States

Site Status

Novo Nordisk Investigational Site

Elkhorn, Nebraska, United States

Site Status

Novo Nordisk Investigational Site

Fremont, Nebraska, United States

Site Status

Novo Nordisk Investigational Site

Omaha, Nebraska, United States

Site Status

Novo Nordisk Investigational Site

Omaha, Nebraska, United States

Site Status

Novo Nordisk Investigational Site

Omaha, Nebraska, United States

Site Status

Novo Nordisk Investigational Site

Omaha, Nebraska, United States

Site Status

Novo Nordisk Investigational Site

Omaha, Nebraska, United States

Site Status

Novo Nordisk Investigational Site

Las Vegas, Nevada, United States

Site Status

Novo Nordisk Investigational Site

Las Vegas, Nevada, United States

Site Status

Novo Nordisk Investigational Site

Las Vegas, Nevada, United States

Site Status

Novo Nordisk Investigational Site

Nashua, New Hampshire, United States

Site Status

Novo Nordisk Investigational Site

East Brunswick, New Jersey, United States

Site Status

Novo Nordisk Investigational Site

Hoboken, New Jersey, United States

Site Status

Novo Nordisk Investigational Site

Albany, New York, United States

Site Status

Novo Nordisk Investigational Site

Lake Success, New York, United States

Site Status

Novo Nordisk Investigational Site

Mineola, New York, United States

Site Status

Novo Nordisk Investigational Site

New Windsor, New York, United States

Site Status

Novo Nordisk Investigational Site

New York, New York, United States

Site Status

Novo Nordisk Investigational Site

North Massapequa, New York, United States

Site Status

Novo Nordisk Investigational Site

Northport, New York, United States

Site Status

Novo Nordisk Investigational Site

Rochester, New York, United States

Site Status

Novo Nordisk Investigational Site

West Seneca, New York, United States

Site Status

Novo Nordisk Investigational Site

Westfield, New York, United States

Site Status

Novo Nordisk Investigational Site

Asheville, North Carolina, United States

Site Status

Novo Nordisk Investigational Site

Asheville, North Carolina, United States

Site Status

Novo Nordisk Investigational Site

Burlington, North Carolina, United States

Site Status

Novo Nordisk Investigational Site

Cary, North Carolina, United States

Site Status

Novo Nordisk Investigational Site

Chapel Hill, North Carolina, United States

Site Status

Novo Nordisk Investigational Site

Charlotte, North Carolina, United States

Site Status

Novo Nordisk Investigational Site

Greenville, North Carolina, United States

Site Status

Novo Nordisk Investigational Site

Lexington, North Carolina, United States

Site Status

Novo Nordisk Investigational Site

Morehead City, North Carolina, United States

Site Status

Novo Nordisk Investigational Site

New Bern, North Carolina, United States

Site Status

Novo Nordisk Investigational Site

Statesville, North Carolina, United States

Site Status

Novo Nordisk Investigational Site

Whiteville, North Carolina, United States

Site Status

Novo Nordisk Investigational Site

Wilmington, North Carolina, United States

Site Status

Novo Nordisk Investigational Site

Winston-Salem, North Carolina, United States

Site Status

Novo Nordisk Investigational Site

Fargo, North Dakota, United States

Site Status

Novo Nordisk Investigational Site

Cincinnati, Ohio, United States

Site Status

Novo Nordisk Investigational Site

Cleveland, Ohio, United States

Site Status

Novo Nordisk Investigational Site

Cleveland, Ohio, United States

Site Status

Novo Nordisk Investigational Site

Cleveland, Ohio, United States

Site Status

Novo Nordisk Investigational Site

Columbus, Ohio, United States

Site Status

Novo Nordisk Investigational Site

Delaware, Ohio, United States

Site Status

Novo Nordisk Investigational Site

Franklin, Ohio, United States

Site Status

Novo Nordisk Investigational Site

Maumee, Ohio, United States

Site Status

Novo Nordisk Investigational Site

Mentor, Ohio, United States

Site Status

Novo Nordisk Investigational Site

Perrysburg, Ohio, United States

Site Status

Novo Nordisk Investigational Site

Norman, Oklahoma, United States

Site Status

Novo Nordisk Investigational Site

Oklahoma City, Oklahoma, United States

Site Status

Novo Nordisk Investigational Site

Portland, Oregon, United States

Site Status

Novo Nordisk Investigational Site

Altoona, Pennsylvania, United States

Site Status

Novo Nordisk Investigational Site

Beaver, Pennsylvania, United States

Site Status

Novo Nordisk Investigational Site

Danville, Pennsylvania, United States

Site Status

Novo Nordisk Investigational Site

Hermitage, Pennsylvania, United States

Site Status

Novo Nordisk Investigational Site

Philadelphia, Pennsylvania, United States

Site Status

Novo Nordisk Investigational Site

Philadelphia, Pennsylvania, United States

Site Status

Novo Nordisk Investigational Site

Pittsburgh, Pennsylvania, United States

Site Status

Novo Nordisk Investigational Site

Pittsburgh, Pennsylvania, United States

Site Status

Novo Nordisk Investigational Site

Smithfield, Pennsylvania, United States

Site Status

Novo Nordisk Investigational Site

Uniontown, Pennsylvania, United States

Site Status

Novo Nordisk Investigational Site

Upper Darby, Pennsylvania, United States

Site Status

Novo Nordisk Investigational Site

Wilkes-Barre, Pennsylvania, United States

Site Status

Novo Nordisk Investigational Site

Anderson, South Carolina, United States

Site Status

Novo Nordisk Investigational Site

Greer, South Carolina, United States

Site Status

Novo Nordisk Investigational Site

Moncks Corner, South Carolina, United States

Site Status

Novo Nordisk Investigational Site

Murrells Inlet, South Carolina, United States

Site Status

Novo Nordisk Investigational Site

Myrtle Beach, South Carolina, United States

Site Status

Novo Nordisk Investigational Site

Orangeburg, South Carolina, United States

Site Status

Novo Nordisk Investigational Site

Spartanburg, South Carolina, United States

Site Status

Novo Nordisk Investigational Site

Chattanooga, Tennessee, United States

Site Status

Novo Nordisk Investigational Site

Chattanooga, Tennessee, United States

Site Status

Novo Nordisk Investigational Site

Chattanooga, Tennessee, United States

Site Status

Novo Nordisk Investigational Site

Kingsport, Tennessee, United States

Site Status

Novo Nordisk Investigational Site

Knoxville, Tennessee, United States

Site Status

Novo Nordisk Investigational Site

Memphis, Tennessee, United States

Site Status

Novo Nordisk Investigational Site

Memphis, Tennessee, United States

Site Status

Novo Nordisk Investigational Site

Nashville, Tennessee, United States

Site Status

Novo Nordisk Investigational Site

Nashville, Tennessee, United States

Site Status

Novo Nordisk Investigational Site

Nashville, Tennessee, United States

Site Status

Novo Nordisk Investigational Site

Tullahoma, Tennessee, United States

Site Status

Novo Nordisk Investigational Site

Arlington, Texas, United States

Site Status

Novo Nordisk Investigational Site

Austin, Texas, United States

Site Status

Novo Nordisk Investigational Site

Austin, Texas, United States

Site Status

Novo Nordisk Investigational Site

Austin, Texas, United States

Site Status

Novo Nordisk Investigational Site

Carrollton, Texas, United States

Site Status

Novo Nordisk Investigational Site

Carrollton, Texas, United States

Site Status

Novo Nordisk Investigational Site

Corpus Christi, Texas, United States

Site Status

Novo Nordisk Investigational Site

Dallas, Texas, United States

Site Status

Novo Nordisk Investigational Site

Dallas, Texas, United States

Site Status

Novo Nordisk Investigational Site

Dallas, Texas, United States

Site Status

Novo Nordisk Investigational Site

Dallas, Texas, United States

Site Status

Novo Nordisk Investigational Site

Fort Worth, Texas, United States

Site Status

Novo Nordisk Investigational Site

Fort Worth, Texas, United States

Site Status

Novo Nordisk Investigational Site

Houston, Texas, United States

Site Status

Novo Nordisk Investigational Site

Houston, Texas, United States

Site Status

Novo Nordisk Investigational Site

Houston, Texas, United States

Site Status

Novo Nordisk Investigational Site

Houston, Texas, United States

Site Status

Novo Nordisk Investigational Site

Houston, Texas, United States

Site Status

Novo Nordisk Investigational Site

Houston, Texas, United States

Site Status

Novo Nordisk Investigational Site

Houston, Texas, United States

Site Status

Novo Nordisk Investigational Site

Houston, Texas, United States

Site Status

Novo Nordisk Investigational Site

Humble, Texas, United States

Site Status

Novo Nordisk Investigational Site

Hurst, Texas, United States

Site Status

Novo Nordisk Investigational Site

Irving, Texas, United States

Site Status

Novo Nordisk Investigational Site

Lewisville, Texas, United States

Site Status

Novo Nordisk Investigational Site

Longview, Texas, United States

Site Status

Novo Nordisk Investigational Site

Lubbock, Texas, United States

Site Status

Novo Nordisk Investigational Site

Midland, Texas, United States

Site Status

Novo Nordisk Investigational Site

Odessa, Texas, United States

Site Status

Novo Nordisk Investigational Site

Pearland, Texas, United States

Site Status

Novo Nordisk Investigational Site

Richardson, Texas, United States

Site Status

Novo Nordisk Investigational Site

Round Rock, Texas, United States

Site Status

Novo Nordisk Investigational Site

San Antonio, Texas, United States

Site Status

Novo Nordisk Investigational Site

San Antonio, Texas, United States

Site Status

Novo Nordisk Investigational Site

San Antonio, Texas, United States

Site Status

Novo Nordisk Investigational Site

San Antonio, Texas, United States

Site Status

Novo Nordisk Investigational Site

Splendora, Texas, United States

Site Status

Novo Nordisk Investigational Site

Sugar Land, Texas, United States

Site Status

Novo Nordisk Investigational Site

Sugar Land, Texas, United States

Site Status

Novo Nordisk Investigational Site

Waco, Texas, United States

Site Status

Novo Nordisk Investigational Site

Salt Lake City, Utah, United States

Site Status

Novo Nordisk Investigational Site

Salt Lake City, Utah, United States

Site Status

Novo Nordisk Investigational Site

Bennington, Vermont, United States

Site Status

Novo Nordisk Investigational Site

South Burlington, Vermont, United States

Site Status

Novo Nordisk Investigational Site

Midlothian, Virginia, United States

Site Status

Novo Nordisk Investigational Site

Norfolk, Virginia, United States

Site Status

Novo Nordisk Investigational Site

Richmond, Virginia, United States

Site Status

Novo Nordisk Investigational Site

Winchester, Virginia, United States

Site Status

Novo Nordisk Investigational Site

Richland, Washington, United States

Site Status

Novo Nordisk Investigational Site

Spokane, Washington, United States

Site Status

Novo Nordisk Investigational Site

Kenosha, Wisconsin, United States

Site Status

Novo Nordisk Investigational Site

Milwaukee, Wisconsin, United States

Site Status

Novo Nordisk Investigational Site

Milwaukee, Wisconsin, United States

Site Status

Novo Nordisk Investigational Site

Algiers, , Algeria

Site Status

Novo Nordisk Investigational Site

Constantine, , Algeria

Site Status

Novo Nordisk Investigational Site

Oran, , Algeria

Site Status

Novo Nordisk Investigational Site

Sidi Bel Abbes, , Algeria

Site Status

Novo Nordisk Investigational Site

CABA, , Argentina

Site Status

Novo Nordisk Investigational Site

Córdoba, , Argentina

Site Status

Novo Nordisk Investigational Site

Mar del Plata, , Argentina

Site Status

Novo Nordisk Investigational Site

Rosario, , Argentina

Site Status

Novo Nordisk Investigational Site

Zárate, , Argentina

Site Status

Novo Nordisk Investigational Site

Fortaleza, Ceará, Brazil

Site Status

Novo Nordisk Investigational Site

Brasília, Federal District, Brazil

Site Status

Novo Nordisk Investigational Site

Aparecida de Goiânia, Goiás, Brazil

Site Status

Novo Nordisk Investigational Site

Belém, Pará, Brazil

Site Status

Novo Nordisk Investigational Site

Mogi das Cruzes, São Paulo, Brazil

Site Status

Novo Nordisk Investigational Site

São Paulo, São Paulo, Brazil

Site Status

Novo Nordisk Investigational Site

São Paulo, São Paulo, Brazil

Site Status

Novo Nordisk Investigational Site

São Paulo, São Paulo, Brazil

Site Status

Novo Nordisk Investigational Site

São Paulo, São Paulo, Brazil

Site Status

Novo Nordisk Investigational Site

Fortaleza, , Brazil

Site Status

Novo Nordisk Investigational Site

Porto Alegre, , Brazil

Site Status

Novo Nordisk Investigational Site

Edmonton, Alberta, Canada

Site Status

Novo Nordisk Investigational Site

Winnipeg, Manitoba, Canada

Site Status

Novo Nordisk Investigational Site

Chatham, Ontario, Canada

Site Status

Novo Nordisk Investigational Site

Ottawa, Ontario, Canada

Site Status

Novo Nordisk Investigational Site

Sarnia, Ontario, Canada

Site Status

Novo Nordisk Investigational Site

Laval, Quebec, Canada

Site Status

Novo Nordisk Investigational Site

Bjelovar, , Croatia

Site Status

Novo Nordisk Investigational Site

Osijek, , Croatia

Site Status

Novo Nordisk Investigational Site

Slavonski Brod, , Croatia

Site Status

Novo Nordisk Investigational Site

Zagreb, , Croatia

Site Status

Novo Nordisk Investigational Site

Zagreb, , Croatia

Site Status

Novo Nordisk Investigational Site

Athens, , Greece

Site Status

Novo Nordisk Investigational Site

Athens, , Greece

Site Status

Novo Nordisk Investigational Site

Athens, , Greece

Site Status

Novo Nordisk Investigational Site

Athens, , Greece

Site Status

Novo Nordisk Investigational Site

Thessaloniki, , Greece

Site Status

Novo Nordisk Investigational Site

Thessaloniki, , Greece

Site Status

Novo Nordisk Investigational Site

Hyderabad, Andhra Pradesh, India

Site Status

Novo Nordisk Investigational Site

Hyderbad, Andhra Pradesh, India

Site Status

Novo Nordisk Investigational Site

Ahmedabad, Gujarat, India

Site Status

Novo Nordisk Investigational Site

Ahmedabad, Gujarat, India

Site Status

Novo Nordisk Investigational Site

Ahmedabad, Gujarat, India

Site Status

Novo Nordisk Investigational Site

Ahmedabad, Gujarat, India

Site Status

Novo Nordisk Investigational Site

Gurgaon, Haryana, India

Site Status

Novo Nordisk Investigational Site

Bangalore, Karnataka, India

Site Status

Novo Nordisk Investigational Site

Bangalore, Karnataka, India

Site Status

Novo Nordisk Investigational Site

Kozhikode, Kerala, India

Site Status

Novo Nordisk Investigational Site

Indore, Madhya Pradesh, India

Site Status

Novo Nordisk Investigational Site

Goa, Maharashtra, India

Site Status

Novo Nordisk Investigational Site

Mumbai, Maharashtra, India

Site Status

Novo Nordisk Investigational Site

Mumbai, Maharashtra, India

Site Status

Novo Nordisk Investigational Site

Mumbai, Maharashtra, India

Site Status

Novo Nordisk Investigational Site

Mumbai, Maharashtra, India

Site Status

Novo Nordisk Investigational Site

Mumbai, Maharashtra, India

Site Status

Novo Nordisk Investigational Site

Pune, Maharashtra, India

Site Status

Novo Nordisk Investigational Site

Pune, Maharashtra, India

Site Status

Novo Nordisk Investigational Site

New Dehli, New Delhi, India

Site Status

Novo Nordisk Investigational Site

Bhubaneswar, Odisha, India

Site Status

Novo Nordisk Investigational Site

Mohali, Punjab, India

Site Status

Novo Nordisk Investigational Site

Chennai, Tamil Nadu, India

Site Status

Novo Nordisk Investigational Site

Chennai, Tamil Nadu, India

Site Status

Novo Nordisk Investigational Site

Coimbatore, Tamil Nadu, India

Site Status

Novo Nordisk Investigational Site

Lucknow, Uttar Pradesh, India

Site Status

Novo Nordisk Investigational Site

Kolkata, West Bengal, India

Site Status

Novo Nordisk Investigational Site

Kolkata, West Bengal, India

Site Status

Novo Nordisk Investigational Site

Ludhiana, , India

Site Status

Novo Nordisk Investigational Site

New Delhi, , India

Site Status

Novo Nordisk Investigational Site

Bari, , Italy

Site Status

Novo Nordisk Investigational Site

Bergamo, , Italy

Site Status

Novo Nordisk Investigational Site

Catanzaro, , Italy

Site Status

Novo Nordisk Investigational Site

Chieti, , Italy

Site Status

Novo Nordisk Investigational Site

Milan, , Italy

Site Status

Novo Nordisk Investigational Site

Milan, , Italy

Site Status

Novo Nordisk Investigational Site

Milano (MI), , Italy

Site Status

Novo Nordisk Investigational Site

Olbia, , Italy

Site Status

Novo Nordisk Investigational Site

Padua, , Italy

Site Status

Novo Nordisk Investigational Site

Palermo, , Italy

Site Status

Novo Nordisk Investigational Site

Ravenna, , Italy

Site Status

Novo Nordisk Investigational Site

Roma, , Italy

Site Status

Novo Nordisk Investigational Site

Roma, , Italy

Site Status

Novo Nordisk Investigational Site

Sesto San Giovanni (MI), , Italy

Site Status

Novo Nordisk Investigational Site

Chuo-ku, Tokyo, , Japan

Site Status

Novo Nordisk Investigational Site

Kanagawa, , Japan

Site Status

Novo Nordisk Investigational Site

Kumamoto, , Japan

Site Status

Novo Nordisk Investigational Site

Miyazaki, , Japan

Site Status

Novo Nordisk Investigational Site

Nagano, , Japan

Site Status

Novo Nordisk Investigational Site

Ota-ku, Tokyo, , Japan

Site Status

Novo Nordisk Investigational Site

Ōta-ku, , Japan

Site Status

Novo Nordisk Investigational Site

Shinjuku-ku, Tokyo, , Japan

Site Status

Novo Nordisk Investigational Site

Alor Star, , Malaysia

Site Status

Novo Nordisk Investigational Site

Kota Samarahan, , Malaysia

Site Status

Novo Nordisk Investigational Site

Kuala Lumpur, , Malaysia

Site Status

Novo Nordisk Investigational Site

Kuantan, , Malaysia

Site Status

Novo Nordisk Investigational Site

Malacca, , Malaysia

Site Status

Novo Nordisk Investigational Site

Serdang, , Malaysia

Site Status

Novo Nordisk Investigational Site

Seremban, , Malaysia

Site Status

Novo Nordisk Investigational Site

Guadalajara, Jalisco, Mexico

Site Status

Novo Nordisk Investigational Site

Guadalajara, Jalisco, Mexico

Site Status

Novo Nordisk Investigational Site

Guadalajara, Jalisco, Mexico

Site Status

Novo Nordisk Investigational Site

Guadalajara, Jalisco, Mexico

Site Status

Novo Nordisk Investigational Site

Guadalajara, Jalisco, Mexico

Site Status

Novo Nordisk Investigational Site

Cuernavaca, Morelos, Mexico

Site Status

Novo Nordisk Investigational Site

Distrito Federal, México, D.F., Mexico

Site Status

Novo Nordisk Investigational Site

Aguascalientes, , Mexico

Site Status

Novo Nordisk Investigational Site

Chihuahua City, , Mexico

Site Status

Novo Nordisk Investigational Site

San Luis Potosí City, , Mexico

Site Status

Novo Nordisk Investigational Site

Bytom, , Poland

Site Status

Novo Nordisk Investigational Site

Gdansk, , Poland

Site Status

Novo Nordisk Investigational Site

Krakow, , Poland

Site Status

Novo Nordisk Investigational Site

Oświęcim, , Poland

Site Status

Novo Nordisk Investigational Site

Poznan, , Poland

Site Status

Novo Nordisk Investigational Site

Szczecin, , Poland

Site Status

Novo Nordisk Investigational Site

Warsaw, , Poland

Site Status

Novo Nordisk Investigational Site

Zamość, , Poland

Site Status

Novo Nordisk Investigational Site

Alba Iulia, Alba, Romania

Site Status

Novo Nordisk Investigational Site

Baia Mare, Maramureş, Romania

Site Status

Novo Nordisk Investigational Site

Târgu Mureş, Mureș County, Romania

Site Status

Novo Nordisk Investigational Site

Ploieşti, Prahova, Romania

Site Status

Novo Nordisk Investigational Site

Kemerovo, , Russia

Site Status

Novo Nordisk Investigational Site

Kirov, , Russia

Site Status

Novo Nordisk Investigational Site

Krasnodar, , Russia

Site Status

Novo Nordisk Investigational Site

Krasnodar, , Russia

Site Status

Novo Nordisk Investigational Site

Moscow, , Russia

Site Status

Novo Nordisk Investigational Site

Moscow, , Russia

Site Status

Novo Nordisk Investigational Site

Nizhny Novgorod, , Russia

Site Status

Novo Nordisk Investigational Site

Rostov-on-Don, , Russia

Site Status

Novo Nordisk Investigational Site

Saint Petersburg, , Russia

Site Status

Novo Nordisk Investigational Site

Saint Petersburg, , Russia

Site Status

Novo Nordisk Investigational Site

Saint Petersburg, , Russia

Site Status

Novo Nordisk Investigational Site

Saint Petersburg, , Russia

Site Status

Novo Nordisk Investigational Site

Saint Petersburg, , Russia

Site Status

Novo Nordisk Investigational Site

Saratov, , Russia

Site Status

Novo Nordisk Investigational Site

Saratov, , Russia

Site Status

Novo Nordisk Investigational Site

Syktyvkar, , Russia

Site Status

Novo Nordisk Investigational Site

Tver', , Russia

Site Status

Novo Nordisk Investigational Site

Tyumen, , Russia

Site Status

Novo Nordisk Investigational Site

Ulyanovsk, , Russia

Site Status

Novo Nordisk Investigational Site

Volgograd, , Russia

Site Status

Novo Nordisk Investigational Site

Yaroslavl, , Russia

Site Status

Novo Nordisk Investigational Site

Yekaterinburg, , Russia

Site Status

Novo Nordisk Investigational Site

Port Elizabeth, Eastern Cape, South Africa

Site Status

Novo Nordisk Investigational Site

Port Elizabeth, Eastern Cape, South Africa

Site Status

Novo Nordisk Investigational Site

Johannesburg, Gauteng, South Africa

Site Status

Novo Nordisk Investigational Site

Johannesburg, Gauteng, South Africa

Site Status

Novo Nordisk Investigational Site

Johannesburg, Gauteng, South Africa

Site Status

Novo Nordisk Investigational Site

Pretoria, Gauteng, South Africa

Site Status

Novo Nordisk Investigational Site

Durban, KwaZulu-Natal, South Africa

Site Status

Novo Nordisk Investigational Site

Durban, KwaZulu-Natal, South Africa

Site Status

Novo Nordisk Investigational Site

eMkhomazi, KwaZulu-Natal, South Africa

Site Status

Novo Nordisk Investigational Site

Middleburg, Mpumalanga, South Africa

Site Status

Novo Nordisk Investigational Site

Brits, North West, South Africa

Site Status

Novo Nordisk Investigational Site

Cape Town, Western Cape, South Africa

Site Status

Novo Nordisk Investigational Site

Cape Town, Western Cape, South Africa

Site Status

Novo Nordisk Investigational Site

Cape Town, Western Cape, South Africa

Site Status

Novo Nordisk Investigational Site

Cape Town, Western Cape, South Africa

Site Status

Novo Nordisk Investigational Site

Goyang, , South Korea

Site Status

Novo Nordisk Investigational Site

Seoul, , South Korea

Site Status

Novo Nordisk Investigational Site

Seoul, , South Korea

Site Status

Novo Nordisk Investigational Site

Suwon-si, Gyeonggi-do, , South Korea

Site Status

Novo Nordisk Investigational Site

Granada, , Spain

Site Status

Novo Nordisk Investigational Site

Granada, , Spain

Site Status

Novo Nordisk Investigational Site

Madrid, , Spain

Site Status

Novo Nordisk Investigational Site

Málaga, , Spain

Site Status

Novo Nordisk Investigational Site

Seville, , Spain

Site Status

Novo Nordisk Investigational Site

Valencia, , Spain

Site Status

Novo Nordisk Investigational Site

Valencia, , Spain

Site Status

Novo Nordisk Investigational Site

Bangkok, , Thailand

Site Status

Novo Nordisk Investigational Site

Bangkok, , Thailand

Site Status

Novo Nordisk Investigational Site

Bangkoknoi, Bangkok, , Thailand

Site Status

Novo Nordisk Investigational Site

Chiang Mai, , Thailand

Site Status

Novo Nordisk Investigational Site

Nakhon Ratchasima, , Thailand

Site Status

Novo Nordisk Investigational Site

Bristol, , United Kingdom

Site Status

Novo Nordisk Investigational Site

Dundee, , United Kingdom

Site Status

Novo Nordisk Investigational Site

Edinburgh, , United Kingdom

Site Status

Novo Nordisk Investigational Site

Guildford, , United Kingdom

Site Status

Novo Nordisk Investigational Site

Norwich, , United Kingdom

Site Status

Novo Nordisk Investigational Site

Nuneaton, , United Kingdom

Site Status

Novo Nordisk Investigational Site

Stevenage, , United Kingdom

Site Status

Novo Nordisk Investigational Site

Wolverhampton, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Algeria Argentina Brazil Canada Croatia Greece India Italy Japan Malaysia Mexico Poland Romania Russia South Africa South Korea Spain Thailand United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Pollock RF, Heller S, Pieber TR, Woo V, Gundgaard J, Hallen N, Luckevich M, Tutkunkardas D, Zinman B; DEVOTE Study Group. Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9). Diabetes Obes Metab. 2019 Jul;21(7):1706-1714. doi: 10.1111/dom.13730. Epub 2019 Apr 14.

Reference Type BACKGROUND
PMID: 30924579 (View on PubMed)

Pollock RF, Valentine WJ, Marso SP, Andersen A, Gundgaard J, Hallen N, Tutkunkardas D, Magnuson EA, Buse JB; DEVOTE study group. Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16). Appl Health Econ Health Policy. 2019 Oct;17(5):615-627. doi: 10.1007/s40258-019-00494-3.

Reference Type BACKGROUND
PMID: 31264138 (View on PubMed)

Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Frandsen KB, Rabol R, Buse JB. Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1. Am Heart J. 2016 Sep;179:175-83. doi: 10.1016/j.ahj.2016.06.004. Epub 2016 Jun 18.

Reference Type RESULT
PMID: 27595693 (View on PubMed)

Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; DEVOTE Study Group. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017 Aug 24;377(8):723-732. doi: 10.1056/NEJMoa1615692. Epub 2017 Jun 12.

Reference Type RESULT
PMID: 28605603 (View on PubMed)

Zinman B, Marso SP, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Lange M, Brown-Frandsen K, Moses A, Ocampo Francisco AM, Barner Lekdorf J, Kvist K, Buse JB; DEVOTE Study Group. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia. 2018 Jan;61(1):48-57. doi: 10.1007/s00125-017-4423-z. Epub 2017 Sep 15.

Reference Type RESULT
PMID: 28913575 (View on PubMed)

Pieber TR, Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pratley RE, Woo V, Heller S, Lange M, Brown-Frandsen K, Moses A, Barner Lekdorf J, Lehmann L, Kvist K, Buse JB; DEVOTE Study Group. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia. 2018 Jan;61(1):58-65. doi: 10.1007/s00125-017-4422-0. Epub 2017 Sep 15.

Reference Type RESULT
PMID: 28913543 (View on PubMed)

Pollock RF, Valentine WJ, Marso SP, Gundgaard J, Hallen N, Hansen LL, Tutkunkardas D, Buse JB; DEVOTE Study Group. DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal-Bolus Regimens for Type 2 Diabetes in the UK. Diabetes Ther. 2018 Jun;9(3):1217-1232. doi: 10.1007/s13300-018-0430-4. Epub 2018 Apr 30.

Reference Type RESULT
PMID: 29713962 (View on PubMed)

Theilgaard H, Mollerup I, Helmark IC, Endahl L, Hoskin S, Hvelplund A, Amby LK, Moses AC. Developing, Planning and Conducting an Interim Analysis: Lessons From the DEVOTE Cardiovascular Outcomes Trial (Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events). Ther Innov Regul Sci. 2019 Mar;53(2):279-286. doi: 10.1177/2168479018776943. Epub 2018 May 24.

Reference Type RESULT
PMID: 29793353 (View on PubMed)

Brown-Frandsen K, Emerson SS, McGuire DK, Pieber TR, Poulter NR, Pratley RE, Zinman B, Ranthe MF, Gron R, Lange M, Moses AC, Orsy P, Buse JB; DEVOTE Study Group. Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10). Diabetes Obes Metab. 2019 Jun;21(6):1437-1444. doi: 10.1111/dom.13677. Epub 2019 Apr 1.

Reference Type RESULT
PMID: 30793465 (View on PubMed)

Pratley RE, Emerson SS, Franek E, Gilbert MP, Marso SP, McGuire DK, Pieber TR, Zinman B, Hansen CT, Hansen MV, Mark T, Moses AC, Buse JB; DEVOTE Study Group. Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7). Diabetes Obes Metab. 2019 Jul;21(7):1625-1633. doi: 10.1111/dom.13699. Epub 2019 Apr 15.

Reference Type RESULT
PMID: 30850995 (View on PubMed)

Bergenstal RM, Hachmann-Nielsen E, Kvist K, Peters AL, Tarp JM, Buse JB. Increased Derived Time in Range Is Associated with Reduced Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and Microvascular Events in Type 2 Diabetes: A Post Hoc Analysis of DEVOTE. Diabetes Technol Ther. 2023 Jun;25(6):378-383. doi: 10.1089/dia.2022.0447. Epub 2023 May 8.

Reference Type DERIVED
PMID: 37017470 (View on PubMed)

Klein KR, Franek E, Marso S, Pieber TR, Pratley RE, Gowda A, Kvist K, Buse JB. Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTE. BMJ Open Diabetes Res Care. 2021 Nov;9(2):e002339. doi: 10.1136/bmjdrc-2021-002339.

Reference Type DERIVED
PMID: 34819298 (View on PubMed)

Amod A, Buse JB, McGuire DK, Pieber TR, Pop-Busui R, Pratley RE, Zinman B, Hansen MB, Jia T, Mark T, Poulter NR; DEVOTE Study Group. Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12). Diab Vasc Dis Res. 2020 Nov-Dec;17(6):1479164120970933. doi: 10.1177/1479164120970933.

Reference Type DERIVED
PMID: 33280425 (View on PubMed)

Heller S, Lingvay I, Marso SP, Philis-Tsimikas A, Pieber TR, Poulter NR, Pratley RE, Hachmann-Nielsen E, Kvist K, Lange M, Moses AC, Andresen MT, Buse JB; DEVOTE Study Group. Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE. Diabetes Obes Metab. 2020 Dec;22(12):2241-2247. doi: 10.1111/dom.14049. Epub 2020 Jul 9.

Reference Type DERIVED
PMID: 32250536 (View on PubMed)

Pratley RE, Husain M, Lingvay I, Pieber TR, Mark T, Saevereid HA, Moller DV, Zinman B; DEVOTE Study Group. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. Cardiovasc Diabetol. 2019 Nov 15;18(1):156. doi: 10.1186/s12933-019-0960-8.

Reference Type DERIVED
PMID: 31729990 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://novonordisk-trials.com

Clinical Trials at Novo Nordisk

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2013-002371-17

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

U1111-1141-7614

Identifier Type: OTHER

Identifier Source: secondary_id

JapicCTI-142464

Identifier Type: REGISTRY

Identifier Source: secondary_id

EX1250-4080

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.